Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A. Scolyer, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1696-1708
Closed Access | Times Cited: 96

Showing 26-50 of 96 citing articles:

Artificial Intelligence for Drug Discovery: An Update and Future Prospects
Harrison Howell, Jeremy McGale, Aurélie Choucair, et al.
Seminars in Nuclear Medicine (2025)
Closed Access
Current efficacy of immune checkpoint inhibitors in microsatellite unstable colorectal cancer and potential biomarkers
Mariam Rojas, Clara Ugueto Rodrigo, Reinaldo Moreno, et al.
(2025) Vol. 4
Open Access
Highlighting recent achievements to advance more effective cancer immunotherapy
Beatrice Belmonte, Sheila Spada, Paola Allavena, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Neoadjuvant Treatment Strategies for Patients with Extremity Soft Tissue Sarcomas Across Europe: A Survey from the Young and Early Career Investigator (Y-Eci) Soft Tissue and Bone Sarcoma Group (Stbsg) of the European Organization for Research and Treatment of Cancer (Eortc)
Stijn van der Burg, Melpomeni Kountouri, Jacco J. de Haan, et al.
(2025)
Closed Access
The evolving treatment landscape for CSCC
David M. Miller
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Systemic Therapy for Melanoma
Ashlee Seldomridge, Roi Weiser, Ashley M. Holder
Surgical Oncology Clinics of North America (2025)
Closed Access
Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy
Nežka Hribernik, Katja Strašek, Andrej Studen, et al.
Radiology and Oncology (2025) Vol. 59, Iss. 1, pp. 43-53
Open Access
Traitements adjuvants et néoadjuvants du mélanome
Joséphine Cazals de Fabel, C. Gaudy‐Marqueste
Bulletin du Cancer (2025)
Open Access
Overcoming common emerging barriers to effective neoadjuvant immunotherapies
Sophia Sokol, Marijo Bilušić
Expert Review of Anticancer Therapy (2025), pp. 1-11
Closed Access
Pathological complete response in metastatic renal cell carcinoma patients treated with cabozantinib plus nivolumab. Case series and literature review.
Marco Stellato, Simone Rota, Mélanie Claps, et al.
Clinical Genitourinary Cancer (2025), pp. 102328-102328
Closed Access
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Tricia R. Cottrell, Michael T. Lotze, Alaa M. Ali, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010928-e010928
Open Access
Melanoma neoadjuvant treatment: review and update of recent trials
Marco Ferrari, Bianca Arianna Facchini, Paolo A. Ascierto, et al.
Expert Review of Anticancer Therapy (2025)
Open Access
Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma
U. J. Nair, Emily Rakestraw, Georgia M. Beasley, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2427-2427
Open Access
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients
Wafik S. El‐Deiry, Catherine Bresson, Fanny Wunder, et al.
Oncotarget (2025) Vol. 16, Iss. 1, pp. 140-162
Open Access
De-escalation of Adjuvant Therapy in Operatively Managed HPV Associated Oropharyngeal Carcinoma: Current Status and Future Directions
J. Daniel, David M. Routman
Seminars in Radiation Oncology (2025) Vol. 35, Iss. 2, pp. 166-172
Closed Access
Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study
Dirk Tomsitz, Petra Zimmermann, Wolfgang G. Kunz, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2025)
Closed Access
Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies
Zhiwei Han, Guomin Chen, Dongchen Wang
Frontiers in Immunology (2025) Vol. 16
Open Access
Addendum 1:Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e006947add1-e006947add1
Open Access
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Teresa Amaral, Margaret Ottaviano, Ana Arance, et al.
Annals of Oncology (2024) Vol. 36, Iss. 1, pp. 10-30
Closed Access | Times Cited: 4
Next-generation combination approaches for immune checkpoint therapy
Sangeeta Goswami, Kristen E. Pauken, Linghua Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 12, pp. 2186-2199
Closed Access | Times Cited: 4
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Wei Yen Chan, Jenny Lee, Ashleigh Stewart, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 3
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions
Laura Marandino, Riccardo Campi, Daniele Amparore, et al.
European Urology Oncology (2024)
Open Access | Times Cited: 3
Two decades of advances in clinical oncology — lessons learned and future directions
Susana Banerjee, Christopher M. Booth, Éduardo Bruera, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 11, pp. 771-780
Closed Access | Times Cited: 3
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial
Jiayong Liu, Xuan Wang, Zhongwu Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out
Andreas M. Schmitt, James Larkin, Sapna P. Patel
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 2

Scroll to top